Pfizer

Pfizer

http://www.pfizer.com
https://www.linkedin.com/company/pfizer/

Pfizer is a publicly owned pharmaceutical and biotechnology company founded in 1849. Headquartered in the United States, it employs approximately 100,900 people. The company's operations encompass research, development, manufacturing, and global distribution of a wide range of healthcare products.

Revenue

Founded

1849

Headcount

100,896

Headquarters

US

Primary Segment

Pharmaceutical Manufacturing

Ownership

Publicly Owned

Subscribe for full access to Pfizer's products in full detail

Subscribe for full access to Pfizer's revenue in full detail

Jul

17th

2025

13:54

Operational Challenges, Negative News, CT_Monitor Company

After recall, Pfizer warns of 'near-term stock out' of penicillin product used to treat syphilis in pregnant women

Pfizer’s multi-year effort to stabilize its U.S. penicillin supply has hit an unexpected hitch after particulate concerns prompted a recall of the company’s long-acting injectable form of the ubiquitous antibiotic. The latest turn in the shortage saga comes at an inopportune time, as rates of syphilis have been on the rise in newborns in recent years.

Jul

17th

2025

13:15

CT_Monitor Company

Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility

WARREN, N.J., July 17, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced the signing of a letter of intent to lease a 17,428-square-foot facility in New Jersey. The facility, formerly occupied by Pfizer and Cordis, a previous division of Johnson & Johnson, should support the Company’s cell therapy manufacturing operations.

Jul

17th

2025

13:04

Pharmaceutical Shifts and Health Innovations Dominate Headlines

The health sector is witnessing notable transformations with drugmakers Bristol Myers and Pfizer announcing a direct-to-patient program for their blood thinner Eliquis, offering it at a 40% discount. This move aims to ease cost burdens for patients requiring this life-saving medication.

Jul

17th

2025

12:10

Drugmakers to Sell Popular Blood Thinner Eliquis at 40% Discount

Drugmakers Pfizer Inc. and Bristol-Myers Squibb Co. will start selling their popular blood thinner Eliquis directly to patients at a cash-pay price of $346 a month. Beginning Sept. 8, patients will be able to purchase the drug directly through Eliquis 360 Support, the drugmakers said in a statement on Thursday.

Jul

17th

2025

11:59

Bristol Myers, Pfizer to Sell Blood Thinner Eliquis Directly to Patients

Drugmakers Bristol Myers and Pfizer said on Thursday that they will make their blood thinner, Eliquis, available directly to cash-paying patients at discounted rate through a new program. Eligible patients will be able to buy the drug directly through the Eliquis 360 Support program from September 8 at a rate that is more than 40% lower than the current list price.

Jul

17th

2025

11:30

New Offerings, CT_Monitor Company

Pharmaceuticals' Patient-Centric Revolution: How Bristol-Myers Squibb and Pfizer's Direct-to-Patient Model for Eliquis Could Reshape Anticoagulant Market Dynamics

The pharmaceutical industry is undergoing a quiet but profound transformation. For decades, the sector's revenue models relied heavily on intermediaries—pharmacies, insurers, and healthcare providers—to bridge the gap between manufacturers and patients. But in 2025, Bristol-Myers Squibb and Pfizer have disrupted this paradigm with a bold, patient-centric innovation: a direct-to-patient (DTP) strategy for Eliquis (apixaban), the world's most prescribed oral anticoagulant.

Jul

17th

2025

10:59

Partnerships and Alliances

Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option

PRINCETON, N.J.--(BUSINESS WIRE)--Jul 17, 2025-- The Bristol Myers Squibb-Pfizer (BMS NYSE: BMY) – (Pfizer NYSE: PFE) Alliance today announced a new direct-to-patient option for purchasing Eliquis ® (apixaban) via our Alliance’s patient resource Eliquis 360 Support.

Associated Press

Jul

17th

2025

10:34

Regulatory and Legal, CT_Monitor Company

Bristol-Myers Squibb et Pfizer proposeront Eliquis en vente directe aux patients à prix réduit dès le 8 septembre

Christopher Boerner, PDG de Bristol-Myers : Un pipeline de 16 traitements, focus sur les neurosciences et l'oncologie

Jul

17th

2025

10:34

Bristol-Myers Squibb and Pfizer will sell Eliquis directly to patients at a discounted cash price starting Sept. 8 - WSJ

July 17 - Bristol-Myers Squibb and Pfizer will sell Eliquis directly to patients at a discounted cash price starting Sept. 8. - WSJ ... -July 17, 2025 at 06:34 am EDT - MarketScreener

Jul

17th

2025

09:54

Events, CT_Monitor Company

Health Ministry meets with Pfizer delegation to strengthen vaccine collaboration

A high-level meeting took place at the Ministry of Health of the Republic of Azerbaijan with a delegation led by Dmitry Kozenkov, Pfizer’s Head for the Caucasus, Central Asia, and Mongolia, reports. Welcoming the delegation, Minister of Health Teymur Musayev highlighted Azerbaijan’s proactive approach during the COVID-19 pandemic, noting that vaccines from four internationally recognized manufacturers were deployed across the country.

Jul

17th

2025

09:34

Events, CT_Monitor Company

From the 21st, up to 500,000 won per participant will be provided

Pfizer Pharmaceutical Korea announced on the 17th that it will start a transportation cost support project as part of the "2025 Zebra Campaign" to improve awareness of rare diseases and support patients. This campaign will be held in collaboration with the Korea Association for Rare and Intractable Diseases and the Community Chest of Korea for the Fever of Love.

Jul

17th

2025

02:37

New Offerings, CT_Monitor Company

Is Pfizer technically bullish or bearish?

As of July 16, 2025, Pfizer 's trend is mildly bullish, supported by positive MACD and Bollinger Bands, but mixed signals from KST and Dow Theory suggest caution. As of 16 July 2025, the technical trend for Pfizer has changed from bullish to mildly bullish.

Analyst insight reports

Protect or plunder Surgical strikes to disrupt industrial-scale piracy

Sustainability in media technology: Understanding the state of sustainability practices

IBC 2024 | Tech wars noise vs. substance

AV broadcast: A buyer's world

Subscribe to access all analyst insight reports